PENTAM 300 Rx
Generic Name and Formulations:
Pentamidine isethionate 300mg/vial; lyophilized pwd for IM or IV inj after reconstitution.
Fresenius Kabi USA
Indications for PENTAM 300:
Pneumonia due to Pneumocystis carinii.
Adults and Children:
<4months: not recommended. Give by deep IM or IV inj. If administered by IV, must infused over 60–120 minutes. ≥4months: 4mg/kg once daily for 14–21 days. Therapy >21 days has been used; but may increase toxicity risk.
Hyper- or hypotension. Ventricular tachycardia. Hypo- or hyperglycemia. Hypocalcemia. Pancreatitis. Leukopenia. Thrombocytopenia. Anemia. Hepatic or renal dysfunction. Stevens-Johnson syndrome. Monitor BP, BUN, serum creatinine, blood glucose, CBC and platelets, liver function (eg, serum bilirubin, alkaline phosphatase, AST/ALT), serum calcium, ECG. Avoid extravasation. Have resuscitation equipment available. Pregnancy (Cat.C; avoid). Nursing mothers: not recommended.
Additive effects with concomitant other nephrotoxic drugs (eg, aminoglycosides, amphotericin B, cisplatin, foscarnet, vancomycin); monitor closely or avoid if possible.
Inj site reactions, severe hypotension, hypoglycemia, diabetes, acute pancreatitis, cardiac arrhythmias, nephrotoxic events (eg, renal dysfunction, elevated serum creatinine, azotemia, renal failure), leukopenia, elevated liver functions tests, anorexia/nausea, rash, pruritus.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Undifferentiated Headaches Common in Children, Adolescents
- Smoking Associated With Increased Relapse Rate in Interferon Beta-Treated Relapsing-Remitting MS
- Frontotemporal Dementia, Frontotemporal Lobar Degeneration Symptoms More Common Later in Life
- No Reduction in Cerebral Perfusion With Intensive Blood Pressure Lowering
- Successful Delirium Prevention in Critically Ill With Dexmedetomidine